<code id='25E35BFD34'></code><style id='25E35BFD34'></style>
      • <acronym id='25E35BFD34'></acronym>
      <center id='25E35BFD34'><center id='25E35BFD34'><tfoot id='25E35BFD34'></tfoot></center><abbr id='25E35BFD34'><dir id='25E35BFD34'><tfoot id='25E35BFD34'></tfoot><noframes id='25E35BFD34'>
      • <optgroup id='25E35BFD34'><strike id='25E35BFD34'><sup id='25E35BFD34'></sup></strike><code id='25E35BFD34'></code></optgroup>
        5. <b id='25E35BFD34'><label id='25E35BFD34'><select id='25E35BFD34'><dt id='25E35BFD34'><span id='25E35BFD34'></span></dt></select></label></b><u id='25E35BFD34'></u>
          <i id='25E35BFD34'><strike id='25E35BFD34'><tt id='25E35BFD34'><pre id='25E35BFD34'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-28 08:42:42 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：8
                                  
                                    
          
                                   
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images
          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.
          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.
          advertisement
          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Readout LOUD: Venture capital, Gilead, and more M&A
                                
                            
          Next article：  
                                      
                                          What does generative AI mean for health care? We asked experts
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles